# A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

> **NCT02804763** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 182 (actual)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dapirolizumab pegol (DZP)

## Key facts

- **NCT ID:** NCT02804763
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-02
- **Primary completion:** 2018-05-31
- **Final completion:** 2018-11-19
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02804763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02804763, "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02804763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*